南山控股(002314.SZ):全資下屬公司5.08億元競得東莞2021WR004號地塊
格隆匯 3 月 10日丨南山控股(002314.SZ)公佈,近日,公司全資下屬公司合肥南山新展房地產開發有限公司以5.08億元競得東莞2021WR004號地塊國有建設用地使用權,並取得成交確認書。
該地塊位於東莞市寮步鎮繆邊社區,地塊面積為10,556.27㎡,地塊用途為城鎮住宅用地、商服用地(R2二類居住用地),土地使用權出讓年限為城鎮住宅用地70年;商服用地40年,1.0<容積率≤2.5。
未來公司不排除就該地塊的項目開發引入合作者,若引入合作者,則會影響公司在該地塊中所佔的權益比例。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.